Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is salivary duct carcinoma?
Salivary duct carcinoma usually begins in the parotid gland, the large salivary gland in front of the ear, though it can arise in other salivary glands. Under the microscope it looks strikingly like an aggressive ductal breast cancer, and that resemblance runs deep: most of these tumors carry the same molecular 'switches' that drive some breast and prostate cancers. The great majority are positive for the androgen receptor (the male-hormone switch), and a sizable share over-express HER2, a growth protein. This matters enormously, because it means the cancer can be attacked not only with surgery and radiation but also with hormone-blocking therapy and HER2-targeted antibodies — turning a once nearly untreatable cancer into one with real targeted options. It is, however, a fast and serious cancer that often involves nerves and lymph nodes, so it is treated promptly and intensively.
The main types
Doctors group salivary duct carcinoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| De novo salivary duct carcinoma | Arises on its own in a previously normal salivary gland; the most common situation. |
| Carcinoma ex pleomorphic adenoma | Develops when a long-standing benign salivary tumor (pleomorphic adenoma) turns malignant into salivary duct carcinoma — a reason not to ignore a slowly growing lump for years. |
| Androgen-receptor-positive / HER2-positive subtypes | Not separate tumors but biomarker groups that decide treatment: AR-positive tumors can respond to hormone blockade, and HER2-positive tumors to HER2-targeted drugs. |
Staging, in plain terms
Staging looks at the size and local spread of the tumor (T), whether it has reached lymph nodes in the neck (N), and whether it has traveled to distant organs such as the lungs or bone (M). Because this cancer is high-grade by nature, even smaller tumors are treated aggressively.
| Head & neck (major salivary gland) TNM | What it generally means |
|---|---|
| Stage I–II | Tumor confined to the gland with no involved nodes. Still treated firmly because of the cancer's aggressive biology. |
| Stage III–IVA/IVB (locally advanced) | Larger tumors, or spread to neck lymph nodes or nearby structures such as the facial nerve. This is the most common way it presents. |
| Stage IVC (distant spread) | Spread to the lungs, bone, or liver. Treated with targeted and systemic therapy aimed at long-term control. |
The standard of care
Salivary Duct Carcinoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery
Complete removal of the gland and tumor (parotidectomy), with effort to preserve the facial nerve when safe, plus removal of neck lymph nodes (neck dissection) because spread to nodes is common.
Radiation after surgery
Almost always recommended for this high-grade cancer to reduce the high risk of local return, covering the tumor bed, nerve pathways, and at-risk neck nodes.
Androgen deprivation therapy (ADT)
For the large majority whose tumors are androgen-receptor-positive, hormone-blocking drugs — the same class used in prostate cancer — can shrink advanced disease and are being studied after surgery to lower recurrence.
HER2-targeted therapy
For HER2-positive tumors, antibodies such as trastuzumab (often with chemotherapy, or as antibody-drug conjugates) produce high response rates in advanced disease — borrowed directly from breast-cancer treatment.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer multiply, while nearby normal tissue repairs itself and recovers. In salivary duct carcinoma, radiation after surgery is a cornerstone because the cancer has a strong tendency to come back locally and to follow nerves toward the skull base. Treatment is given as short, painless daily sessions over several weeks. It uses no radioactive implants and leaves no radioactivity behind, so you remain completely safe to be around others, including children, throughout the course.
The main ways radiation is delivered for salivary duct carcinoma:
Intensity-modulated radiation therapy (IMRT)
Computer-shaped x-ray beams deliver a high, conformal dose to the gland bed and neck while protecting the opposite salivary gland, swallowing muscles, and spinal cord to limit dry mouth and swallowing problems.
Proton therapy
Protons stop at the tumor and spare tissue beyond it, useful for reducing dose to the brain, inner ear, and opposite side of the head in selected parotid tumors.
Neutron or carbon-ion therapy (selected centers)
Heavy-particle beams hit harder than x-rays and are sometimes used for bulky or radioresistant salivary tumors at specialized centers.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Survival benefit from HER2-targeted and androgen-blocking therapy: Studies show patients with HER2-positive or AR-positive salivary duct carcinoma who receive matched targeted therapy live significantly longer than those who do not, establishing biomarker testing as essential.[1]
PMC9459484 (2022); Cancer Treatment Reviews (2025)
Trastuzumab plus chemotherapy yields high responses: In HER2-positive/AR-positive disease, trastuzumab with docetaxel produced an objective response rate above 70% with durable benefit, outperforming combined androgen blockade in that group.[2]
Comprehensive review, Cancer Treatment Reviews S0305-7372(25)00115-X
Definitive ADT plus radiation for unresectable disease: Androgen deprivation combined with external-beam radiation has controlled locally advanced AR-positive tumors that could not be removed surgically, offering a non-surgical option.[3]
PubMed 23720164; case series (2023–2025)
Common questions
Why does my salivary cancer get treated like a breast cancer? Because biologically it often is very similar. Salivary duct carcinoma frequently carries the HER2 growth protein and the androgen (hormone) receptor — the same targets seen in breast and prostate cancers — so the same antibodies and hormone-blocking pills can work against it. That's why your tumor is tested for these markers.
Will I lose movement in my face? Surgeons work hard to preserve the facial nerve that runs through the parotid gland, and often can. If the tumor has grown into the nerve, it may need to be removed, but reconstructive techniques and rehabilitation can restore much function and appearance.
Is this cancer curable? It is aggressive, but combining surgery, radiation, and — when the markers fit — targeted hormone or HER2 therapy has meaningfully improved outcomes. Early, complete treatment offers the best chance of cure, and targeted drugs give strong options even when the disease is advanced.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- PMC9459484 (2022); Cancer Treatment Reviews (2025) (no indexed identifier — see your care team) ↩
- Comprehensive review, Cancer Treatment Reviews S0305-7372(25)00115-X (no indexed identifier — see your care team) ↩
- PubMed 23720164; case series (2023–2025) (no indexed identifier — see your care team) ↩